RE:RE:RE:RE:Aggghhhh..Agreed that their analysis has little weight to it. Also, it's a sell-side firm and in 2015 they were quite happy to rate CXR a buy when it was trading at 81$. Always a flipside.
Lumberfeverlong wrote: Can anyone verify if and when Mackie took a short position on the stock? They are a third tier firm. I would not put too much credence in their analysis. By their statements, they would have you beleive that there is no place in the market place for companies selling generic drugs, which we all know is complete BS as generic drug companies have played a major role in the pharmaceutical industry for decades.